MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a study protocol for a multicenter, double-blind, randomised, placebo-controlled phase II trial.

Elisa R ZanierFrancesca PischiuttaEliana RulliAlessia VargioluFrancesca ElliPaolo GrittiGiuseppe GaipaDaniela BelottiGianpaolo BassoTommaso ZoerleNino StocchettiGuiseppe Citerionull null

Published in: Intensive care medicine experimental (2023)

Overall, the MATRIx trial is a critical step towards developing an effective treatment for TBI, which could significantly improve the lives of millions worldwide affected by this debilitating condition. Trial Registration EudraCT: 2022-000680-49.

Keyphrases

placebo controlled
double blind
phase iii
traumatic brain injury
phase ii
study protocol
clinical trial
open label
phase ii study
severe traumatic brain injury
randomized controlled trial
bone marrow
radiation therapy
cross sectional
combination therapy
replacement therapy